Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.839
+0.004 (0.47%)
At close: Mar 9, 2026, 4:00 PM EDT
0.850
+0.011 (1.31%)
After-hours: Mar 9, 2026, 7:59 PM EDT
Citius Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2020 - 2016 |
| Cash & Equivalents | 7.72 | 4.25 | 3.25 | 26.48 | 41.71 | 70.07 | Upgrade
|
| Cash & Short-Term Investments | 7.72 | 4.25 | 3.25 | 26.48 | 41.71 | 70.07 | Upgrade
|
| Cash Growth | 601.89% | 30.76% | -87.72% | -36.51% | -40.47% | 405.59% | Upgrade
|
| Receivables | 4.05 | - | - | - | - | - | Upgrade
|
| Inventory | 22.64 | 22.29 | 8.27 | - | - | - | Upgrade
|
| Prepaid Expenses | 3.54 | 1.4 | 2.7 | 7.89 | 2.85 | 2.74 | Upgrade
|
| Total Current Assets | 37.95 | 27.93 | 14.22 | 34.37 | 44.56 | 72.81 | Upgrade
|
| Property, Plant & Equipment | 0.84 | 0.82 | 0.25 | 0.46 | 0.65 | 0.83 | Upgrade
|
| Goodwill | 9.35 | 9.35 | 9.35 | 9.35 | 9.35 | 9.35 | Upgrade
|
| Other Intangible Assets | 92.23 | 92.8 | 92.8 | 59.4 | 59.4 | 59.4 | Upgrade
|
| Other Long-Term Assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | Upgrade
|
| Total Assets | 140.39 | 130.94 | 116.65 | 103.61 | 114 | 142.43 | Upgrade
|
| Accounts Payable | 11.02 | 13.69 | 4.93 | 2.93 | 1.17 | 1.28 | Upgrade
|
| Accrued Expenses | 7.79 | 7.48 | 2.25 | 2.63 | 3.17 | 2.53 | Upgrade
|
| Short-Term Debt | 1 | 1 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 0.15 | 0.09 | 0.24 | 0.22 | 0.2 | 0.18 | Upgrade
|
| Other Current Liabilities | 18.25 | 22.65 | 28.4 | - | - | - | Upgrade
|
| Total Current Liabilities | 38.21 | 44.91 | 35.81 | 5.78 | 4.53 | 3.98 | Upgrade
|
| Long-Term Leases | 0.68 | 0.72 | 0.02 | 0.26 | 0.48 | 0.68 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 8.04 | 7.77 | 6.71 | 6.14 | 5.56 | 4.99 | Upgrade
|
| Total Liabilities | 46.92 | 53.41 | 42.55 | 12.18 | 10.57 | 9.65 | Upgrade
|
| Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.15 | 0.15 | Upgrade
|
| Additional Paid-In Capital | 326.96 | 306.34 | 271.44 | 253.06 | 232.37 | 228.08 | Upgrade
|
| Retained Earnings | -247.02 | -238.8 | -201.37 | -162.23 | -129.69 | -96.05 | Upgrade
|
| Total Common Equity | 79.96 | 67.55 | 70.08 | 90.83 | 102.83 | 132.18 | Upgrade
|
| Minority Interest | 13.51 | 9.98 | 4.02 | 0.6 | 0.6 | 0.6 | Upgrade
|
| Shareholders' Equity | 93.47 | 77.53 | 74.1 | 91.43 | 103.43 | 132.78 | Upgrade
|
| Total Liabilities & Equity | 140.39 | 130.94 | 116.65 | 103.61 | 114 | 142.43 | Upgrade
|
| Total Debt | 1.83 | 1.81 | 0.26 | 0.48 | 0.68 | 0.86 | Upgrade
|
| Net Cash (Debt) | 5.89 | 2.44 | 2.99 | 26 | 41.03 | 69.22 | Upgrade
|
| Net Cash Growth | 557.92% | -18.40% | -88.50% | -36.64% | -40.72% | 453.40% | Upgrade
|
| Net Cash Per Share | 0.40 | 0.22 | 0.44 | 4.30 | 7.02 | 15.93 | Upgrade
|
| Filing Date Shares Outstanding | 22.38 | 20.76 | 7.73 | 6.36 | 5.85 | 5.84 | Upgrade
|
| Total Common Shares Outstanding | 22.38 | 18.07 | 7.25 | 6.35 | 5.85 | 5.84 | Upgrade
|
| Working Capital | -0.26 | -16.98 | -21.59 | 28.59 | 40.03 | 68.83 | Upgrade
|
| Book Value Per Share | 3.57 | 3.74 | 9.67 | 14.29 | 17.58 | 22.64 | Upgrade
|
| Tangible Book Value | -21.62 | -34.6 | -32.07 | 22.08 | 34.08 | 63.44 | Upgrade
|
| Tangible Book Value Per Share | -0.97 | -1.91 | -4.43 | 3.48 | 5.83 | 10.86 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.